We evaluated an enzyme-linked immunosorbent assay (ELISA) for detecting anti-Jo-1 antibodies in patients with polymyositis (PM ) or dermatomyositis (DM ) by use of the recombinant fusion protein Jo-1. Sera from 64 patients with PM or DM, from 80 patients with other connective tissue diseases, and from 64 healthy subjects matched for age, sex and race, were studied by the ELISA and by the double immunodiffusion (DID) method. Eight patients with myositis (six PM, one DM and one DM with malignancy) with positive anti-Jo-1 by DID also showed positive results by the ELISA method, whereas five patients with positive anti-Jo-1 by this ELISA showed negative results on DID. One of the five had non-specific results. The incidence of positive results for anti-Jo-1 with the ELISA (18.8%) was greater than that for DID (12.5%), but the difference was not statistically significant. All patients with positive results for anti-Jo-1 by DID were also positive by the ELISA. The ELISA system with the recombinant Jo-1 antigen was useful in the detection of anti-Jo-1 antibodies in patients with PM/DM.
V autoantibodies to nuclear and cytoplasmic PATIENTS AND METHODS antigens are characteristic of patients with polymyositis Patients (PM ) and dermatomyositis (DM ). Among the antiSerum samples of 64 Japanese patients with idiogens to which these autoantibodies are targeted are pathic inflammatory muscle diseases were studied. aminoacyl-tRNA synthetases [histidyl-tRNA syntheThere were 19 males and 45 females, aged 15-85 (mean 50.9) yr. These cases consisted of 21 PM, 19 DM, 11 tase (Jo-1), threonyl-tRNA synthetase (PL-7), alanyl-PM/DM with another connective tissue disease, three tRNA synthetase (PL-12), isoleucyl-tRNA synthetase childhood DM and 10 DM with malignancies. Serum (OJ ) and glycyl-tRNA synthetase ( EJ )], signal recognisamples were also obtained from 20 patients with tion particle (SRP), Mi-2, PM-Scl and Ku [1] . The systemic lupus erythematosus (SLE ), 20 patients with anti-Jo-1 antibody [2] is most common, and is clinically systemic sclerosis, 20 patients with rheumatoid arthritis the most important, as a marker antibody for PM, (RA) and 20 patients with primary Sjö gren's synespecially in those patients with interstitial lung drome. Diagnoses of PM and DM were based on the disease [3] .
criteria of Bohan and Peter [17] . All 64 patients were Anti-Jo-1 antibodies had been estimated variously diagnosed as 'definite' or 'probable' PM/DM. Fifteen by double immunodiffusion (DID) [2, 3] , counteradditional 'possible' PM/DM cases were also tested. immunoelectrophoresis [4, 5] , Western blotting [6 ] ,
The diagnoses of SLE, systemic sclerosis and RA were enzyme-linked immunosorbent assay ( ELISA) using based on ARA criteria [18] [19] [20] . Sjö gren's syndrome the column-purified Jo-1 antigen [6, 7] , or the enzyme was diagnosed by the criteria of the Ministry of Health inhibitory activity method [6 ] .
and Welfare of Japan [21] . Interstitial lung disease was Recently, an ELISA with recombinant fusion prodiagnosed on the basis of persistent bibasilar infiltrates teins has been substituted for DID in the detection of on chest roentgenogram together with persistent crepvarious autoantibodies, such as antibodies to Sm [8] , itations on auscultation. nRNP [9] , Ro(SSA) [10], La(SSB) [11] , topoisoIn addition, 64 serum samples of healthy subjects merase- 1 [12] and centromere (CEMP-B) [13] . Antimatched for age, sex and race to the 64 PM/DM Mi-2 antibody [14, 15] , a DM-specific autoantibody patients were evaluated. These subjects were employees [14] , is also useful in an ELISA system using recombinof our hospital and students of our nurses' school. ant antigen [16 ] .
There are no previous published reports of an ELISA Double immunodiffusion system with recombinant fusion Jo-1 antigen for the A kit to detect anti-Jo-1 antibodies in serum ( ENA-4 detection of anti-Jo-1 antibodies; this is the first such Test; Medical and Biological Laboratories, Inc., report. Nagoya, Japan) was used for the DID procedure.
Crude pig spleen extracts were the source of the Jo-1 antigen.
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nucleic acid (cDNA) was isolated from a cDNA library (Clonetech Laboratories, Inc., Palo Alto, CA, USA) added and incubated for 30 min at room temperature. The reaction was stopped by 0.1  phosphate. obtained from KB cells (human pharyngeal epidermoid carcinoma cell lines). Two cDNA fragments of 1530
Plates were read by a microplate reader MPR-A4i ( Tohsoh, Co., Tokyo, Japan) at 450 nm. Each sample base pairs were generated by polymerase chain reaction with primer pairs. The primers were designed as was estimated in duplicate. For controls, antibodies to recombinant Sm antigen 5∞-CAACCACCGCAGGTCGAGA-3∞ and 5∞-GTA-GTGCCAGTCCCACTTCCT-3∞. This step was fol-(Immunovision, Co., Springdale, AR, USA) and to GST were estimated using the same ELISA system. lowed by cloning into the plasmid pGEM-T Vector System (Promega Co., Madison, WI, USA). The Jo-1 cDNA was subcloned into a pGEX-3 vector
Inhibition test Inhibition of ELISA activity of the anti-Jo-1-positive (Pharmacia Biotech, Uppsala, Sweden) for transformation of Escherichia coli (strain NM522). Expression of sera was carried out simultaneously by the recombinant GST-Jo-1 antigen and native column-purified Sm antithe Jo-1 protein was induced by 1 m isopropyl-b--thiogalactopyranoside. The E. coli cells were harvested gen (Immunovision, Springdale, AR, USA) as control.
If the binding of these sera was not inhibited significby centrifugation. The E. coli pellet was resuspended in 10 m Tris-HCl (pH 8.0), 20% sucrose and 1 m antly [>50% of optical density (OD)] by the recombinant GST-Jo-1 antigen, it was considered a sign of non-EDTA (pH 7.6), and was dissolved in 50 m Tris-HCl, 100 m NaCl, 2 m phenylmethylsulphonyl fluoride specific binding or of binding to a contaminant. (PMSF ), 2 mg/ml pepstatin A and 2 mg/ml leupepsin (pH 7.5). After disruption of E. coli and its DNA by Statistical methods x2 tests with correction were used for 2×2 tables. a sonicator ( VD201; Tomy, Tokyo, Japan) under the conditions of 'output' at 5 for 30 min was repeated RESULTS four times, this solution was layered onto 40% (w/v) sucrose, 10 m Tris-HCl (pH 7.5), 100 m NaCl, Purity and antigenic specificity of the recombinant GST-Jo-1 antigen 1 m EDTAΩ2Na and 1 m PMSF. The solution was centrifuged at 13 000 g at 4°C for 60 min. The pellet SDS-PAGE analysis of the recombinant GST-Jo-1 fusion protein showed a 76 kDa main band, which is containing inclusion bodies in which the recombinant Jo-1 protein glutathione-S-transferase (GST )-Jo-1 rescompatible with the molecular weight (MW ) of a complex of two proteins: GST (MW=25 kDa) and ides was solubilized by pipetting and sonication in 6  urea, 10 m Tris-HCl (pH 7.5) and 1 m PMSF.
Jo-1 protein (MW~50 kDa) [5, 23] . The main band had~90% homogeneity, as determined by Coomassie The protein concentration was measured using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, blue staining on SDS-PAGE (Fig. 1) . The main band and the thinner band located just beneath it, which Hercules, CA, USA). The purity of the GST-Jo-1 was examined on 12.5% polyacrylamide gels by sodium was possibly a degradation product of the main band, had Jo-1 antigenic activity, as confirmed by the immunododecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE ). The Jo-1 antigenic activity of the blotting procedure (data not shown). GST-Jo-1 was examined by the Western blotting method, as described previously [22] .
ELISA
For the ELISA, 10 mg protein/ml of the GST-Jo-1 antigen dissolved in 10 m Tris-HCl (pH 7.6), 6  urea and 0.01% b-octyl-glucoside was prepared. Polystyrene microtitre plates with a flat bottom (Nunc Maxisoap; Intermed, Co., Roskilde, Denmark) were coated with 100 ml of the GST-Jo-1 antigen solution overnight at 4°C. Blocking of the sensitized wells was carried out with phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA) (Intergen Co., New York, USA) and 5% sucrose for 2 h at room temperature (20-25°C ). The plates were dried. Then 100 ml/well of the sera to be tested were diluted 1:200 in PBS (pH 7.4), and 1% BSA was added. This was incubated for 1 h at room temperature. After four washings with PBS (pH 7.4) and 0.1% Tween 20, 100 ml/well of horseradish peroxidase-conjugated mouse anti-human c-chain (Medical and Biological After four washings with the same buffer, 100 ml/well b, purified recombinant fusion protein (GST-Jo-1) with different protein concentrations. of 3,3∞,5,5∞-tetramethylbenzidine as substrate were Anti-Jo-1 ELISA Sera from the 64 healthy control subjects produced a mean ± 3 .. OD 450 for Jo-1 binding of 1.29 ± 3.70 absorbance units (AU ). The assay result was considered positive if the OD 450 value at a serum dilution of 1:100 was Á5.0 AU.
The incidence of anti-Jo-1 antibodies in the ELISA and DID, and the actual AU values in the ELISA, are shown in Table I and Fig. 2 , respectively. In the ELISA system, 13 patients showed positive results (Á5 AU). The positive sera of 12 of the 13 patients were specifically absorbed by the GST-Jo-1 antigen. However, the anti-GST ELISA of all 13 anti-Jo-1-positive sera yielded negative results. Representative results of the absorption tests are shown in Fig. 3 .
In one PM patient, the positive anti-Jo-1 activity was absorbed not only by the GST-Jo-1 antigen, but also by the Sm antigen used as the control. This patient's serum contained two precipitin lines in DID, but their antigenic specificities differed from the Jo-1 and the Sm antibody system. In the other 12 patients positive for anti-GST-Jo-1, four had negative DID results: one had DM alone, one had PM-SLE overlap, one had DM with malignancy and one had Sjö gren's syndrome with polyarthritis and elevated serum creat- antibodies were lacking in three (37%) of eight PM patients with interstitial lung disease. All patients who were positive for anti-Jo-1 by DID also had positive interstitial lung disease, arthritis and Raynaud's phenomenon. results in the ELISA system. No patients tested positive for anti-Jo-1 in DID but not in the ELISA system. DISCUSSION Among the 15 patients with a diagnosis of 'possible' PM/DM, one tested positive for anti-Jo-1 in the An ELISA that uses recombinant antigens has replaced DID in tertiary care hospitals in Japan and ELISA, but not in DID. This patient exhibited Healthy controlssynthetase syndrome [27] . 'Possible' PM/DM could be an appropriate diagnosis for this distinct subset of idiopathic inflammatory myopathies. Recent advances in serology suggest that a disease entity should be established by its serological characteristics as well as by its clinical and pathological characteristics. Revised criteria for SLE [18] , RA [20] and Sjö gren's syndrome [28] reflect this concept. For more than 20 yr, however, physicians have used the diagnostic criteria for PM/DM [17] which lack serological factors as elements of diagnosis. The classification criteria for PM/DM as recently reported in Japan [29] have introduced the Jo-1 antibody as a diagnostic criterion for PM/DM.
In conclusion, an ELISA system that employed the antigens, respectively.
